All In Biotech

Drug Trial Radar · NCT07251491

Psilocybin to Treat Depression in Spinal Cord Injury

Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Aug 6, 2026

Primary completion

Mar 1, 2028

Study completion Mar 1, 2028

Sponsor

Sponsor type
Federal agency
Collaborators
Bronx Veterans Medical Research Foundation, Inc; Usona Institute; United States Department of Defense
First posted
Nov 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of this study is to determine if psilocybin is safe for use in people with SCI. The study will measure how people with SCI respond to three psilocybin doses: low (5mg), medium (10mg), and high (25mg). The main question the study aims to answer is: does psilocybin increase the number and severity of adverse (bad) events reported by people with SCI? These may include pain, muscle spasms, symptoms of depression, and symptoms of low or high blood pressure. The investigators will also measure how well people with SCI tolerate the psychedelic experience, and compare responses between the low (5mg), medium (10mg), and high (25mg) doses. Participants will: * Agree to be enrolled in the study for up to 13 months. * Agree to complete the seven (7) visits that are included in the psilocybin-assisted therapy. * Agree to complete follow-up study visits, including in-person visits to the James J Peters VA Medical Center, located in the Bronx, New York and remote visits. * Agree to keep a log of how they are feeling and any change in the frequency or severity of adverse events.

Conditions

  • Spinal Cord Injury
  • Depression - Major Depressive Disorder
  • Veteran

Interventions

  • Psilocybin (Usona Institute)Drug

    Oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Related Adverse Events as Assessed by the Adverse Events Log.Time frame: Screening through study completion, an average of 13 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • James J. Peters Department of Veterans Affairs Medical Center

    The Bronx, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.